TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 776350
Drug: Practolol 600
Normalized name: (±)-practolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol 600 mg/day
Study: 30905211
Drug: ICS/LABA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS/LABA treatment
Study: 25875383
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG) doses of 10, 20, 30, and 40 μg
Study: 21865363
Drug: Low-dose pioglitazone-flutamide-metformin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pioglitazone-flutamide-metformin (PioFluMet)
Study: 19262436
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.25 mg/0.05 mL) before PRP
Study: 22809091
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination brimonidine-timolol (FCBT)
Study: 17407624
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination dorzolamide-timolol (FCDT)
Study: 9711427
Drug: Gemfibrozil therapy
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil therapy for 12 weeks
Study: 8040675
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/d orally
Study: 8040675
Drug: MPA 1
Normalized name: Fycompa 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA 1 g/d orally
Study: 2689895
Drug: Substitution therapy
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitution therapy with thyroxine
Study: 791472
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluorouracil, methyl‐CCNU, and vincristine
Study: 24632426
Drug: Selective pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective pulmonary perfusion (sPP) with venous blood at 2°C, 4 l
Study: 17921377
Drug: Glucose and
Normalized name: Glucose and treacle only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose and 2.4 g amino acid kg(‐1) d(‐1)
Study: 16076947
Drug: Pegvisomant (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (10 mg/d)
Study: 11966672
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg moclobemide coadministration with 40 mg omeprazole
Study: 11966672
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole alone
Study: 7137540
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg bupivacaine
Study: 7137540
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg prilocaine
Study: 24665578
Drug: Histamine concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine concentrations of 1 mg/mL
Study: 24665578
Drug: Histamine concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine concentrations of less than 2 mg/mL
Study: 22926408
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (100-μg bolus)
Study: 15657908
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MRSI and MRI data
Study: 9468365
Drug: Ritonavir, lamivudine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir, lamivudine, and zidovudine (triple combination treatment)
Study: 9468365
Drug: Ritonavir monotherapy
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir monotherapy (initial treatment before adding lamivudine and zidovudine)
Study: 8521898
Drug: Intravenous thyrotropin-releasing
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thyrotropin-releasing hormone (TRH) 200 micrograms
Study: 2222550
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release propranolol (160 mg)
Study: 2222550
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol tablet (80 mg)
Study: 2222550
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol tablet
Study: 29882696
Drug: Propofol post-conditioning
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol post-conditioning (Cp 1.2 µg/mL)
Study: 29098740
Drug: Noncontact low-frequency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncontact low-frequency ultrasound (NLFU) treatment
Study: 15694559
Drug: Tiagabine b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine b.i.d. (twice daily)
Study: 15694559
Drug: Tiagabine t.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine t.i.d. (three times daily)
Study: 12413995
Drug: Standard long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard long GnRH agonist (GnRH-a)-gonadotropin stimulation
Study: 9856877
Drug: Epsilon‐aminocaproic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epsilon‐aminocaproic acid (EACA) 100 mg/kg at cannulation followed by 25 mg/kg/h for 72 hours
Study: 2146067
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of isophane (NPH) insulin
Study: 2146067
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of isophane (NPH) insulin
Study: 147656
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing cyproterone acetate
Study: 147656
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing d-norgestrel
Study: 147656
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without hormonal medication)
Study: 12469457
Drug: Parenteral nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutritional support (Group B)
Study: 19741029
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) intervention (n = 21)
Study: 28490349
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) intervention
Study: 15667429
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean dosage 16.2 +/- 4.8 mg/day)
Study: 15667429
Drug: Clozapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (mean dosage 209 +/- 91 mg/day)
Study: 9934940
Drug: Intranasal vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal vasopressin (20 IU before bedtime and after awakening)
Study: 619934
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release tablet containing 300 mg of papaverine hydrochloride
Study: 619934
Drug: Capsule containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing 300 mg of papaverine hydrochloride
Study: 17722957
Drug: 3-week cycles
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week cycles of intravenous (IV) docetaxel plus cisplatin and fluorouracil (5-fluorouracil)
Study: 16252573
Drug: Rivastigmine 3‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 3‐6 mg twice daily for 20 weeks
Study: 11697709
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (0.3 g/kg in a 4-week cycle until the 28th to 32nd week of gestation), aspirin (100 mg/d), and certoparin (3,000 anti-Xa U/d)
Study: 11697709
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (aspirin and low‐molecular‐weight heparin)
Study: 7998586
Drug: rilmenidine 1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine 1-2 mg/day (n = 46)
Study: 7998586
Drug: Hydrochlorothiazide (HCZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCZ) 25-50 mg/day (n = 42)
Study: 3056208
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (1%) at induction of anaesthesia
Study: 28430748
Drug: Vero cell‐derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero cell‐derived inactivated JE virus vaccine (IXIARO), 0.25 mL for <3 years and 0.5 mL for ≥3 years, administered 28 days apart
Study: 25881753
Drug: Pomaglumetad methionil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomaglumetad methionil 400 mg
Study: 20027348
Drug: Anaferon (pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaferon (pediatric formulation) as a component of complex therapy
Study: 16495392
Drug: Glucosamine 1500
Normalized name: glucosamine 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine 1500 mg daily
Study: 16495392
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate 1200 mg daily
Study: 16495392
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (glucosamine and chondroitin sulfate) in moderate-to-severe pain
Study: 11134125
Drug: Estradiol therapy
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol therapy (transdermal or oral)
Study: 3351823
Drug: Cefonicid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (1 g preoperative dose)
Study: 3351823
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g preoperative and postoperative for a total of four doses)
Study: 21122270
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment for 6 months
Study: 12079904
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA hepatitis B vaccine (3 doses: 2nd and 3rd doses at 1 and 6 months)
Study: 12079904
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA hepatitis B vaccine
Study: 2162877
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic (Moduretic; Merck Sharp & Dohme)
Study: 2162877
Drug: Beta-blocking agent
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocking agent (atenolol)
Study: 6177804
Drug: Antiviral activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral activity in acute-phase sera
Study: 17650171
Drug: Soaking in
Normalized name: magnesium sulfate
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Soaking in an alkaline peroxide solution (Bonyplus)
Study: 17650171
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of soaking and brushing (methods 2 and 3)
Study: 17650171
Drug: Brushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing with dentifrice (Dentu‐Creme) and soft Oral B toothbrush
Study: 17650171
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of soaking and brushing (methods 2 and 5)
Study: 16301884
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg/kg IV) + remifentanil (1 microg/kg)
Study: 16301884
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg/kg IV)
Study: 11896441
Drug: dl1520 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dl1520 gene therapy
Study: 11896441
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection (control group)
Study: 9790607
Drug: Assessment-driven algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment-driven algorithm for treatment of pediatric status asthmaticus
Study: 9790607
Drug: Unstructured standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unstructured standard treatment
Study: 2533582
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg s.I.)
Study: 342627
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza virus vaccine (200 CCA units of influenza A/New Jersey/76 and 200 CCA units of influenza A/Victoria/75)
Study: 9269055
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza virus vaccine
Study: 31096775
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vericiguat
Study: 31096775
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg vericiguat
Study: 22121861
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of antipsychotic treatment for at least 6 months
Study: 22121861
Drug: Gradual withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual withdrawal of antipsychotic treatment
Study: 12473554
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin C (25 mg/min; IA)
Study: 7707809
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms TRH intravenously every 12 h up to a maximum of four doses
Study: 7707809
Drug: Placebo intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenously every 12 h up to a maximum of four doses
Study: 22006502
Drug: Topical silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silver sulfadiazine (SSD) cream 1%, three times a day, 3 days a week, for 5 weeks during radiotherapy and one week thereafter
Study: 9389807
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d P vaginally
Study: 9389807
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d P vaginally
Study: 9389807
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d P vaginally
Study: 3229874
Drug: Acetyl-L-carnitine, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine, 2 g/day for three months
Study: 23448854
Drug: Emergency medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency medicine residents (EM)
Study: 21122200
Drug: Simvastatin and
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin and Aspirin
Study: 18055141
Drug: Methacholine dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine dry powder inhaler (12.5 to 200 microg per metered dose)
Study: 18055141
Drug: Methacholine solution
Normalized name: methacholine Ophthalmic Solution
DrugBank: Methacholine (DB06709)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methacholine solution
Study: 15781524
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg single-dose extended-release epidural morphine (EREM)
Study: 15781524
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg single-dose EREM
Study: 15781524
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg single-dose EREM
Study: 15781524
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg single-dose EREM
Study: 15781524
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg standard epidural morphine sulfate (MS)
Study: 15781524
Drug: Single-dose EREM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose EREM (all doses)
Study: 15781524
Drug: Single-dose EREM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose EREM (15, 20, and 25 mg)
Study: 8644802
Drug: Surgery (pars
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery (pars plana vitrectomy with C3F8 injection and face-down positioning for two weeks)
Study: 1440484
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin plus dihydroergotamine (DHE; 0.5 mg, given 8 hourly by sc injection)
Study: 1440484
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin alone (5,000 IU sodium heparin given subcutaneously [sc] 8 hourly until the seventh postoperative day)
Study: 28419624
Drug: Reboxetine 12
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 12 mg
Study: 27400948
Drug: Irinotecan 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 60 mg/m² on days 1, 8, and 15 plus cisplatin 60 mg/m² on day 1 (CPT-P group) every 4 weeks for six cycles
Study: 27400948
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m² plus carboplatin AUC 6.0 mg/mL/min on day 1 (TC group) every 3 weeks for six cycles
Study: 25929209
Drug: Covered implant
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Covered implant set
Study: 25929209
Drug: Uncovered implant
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncovered implant set
Study: 24124358
Drug: salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol/fluticasone propionate (SFC) 50/250 μg twice daily
Study: 24124358
Drug: tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tiotropium bromide 18 μg once daily
Study: 24124358
Drug: TRIPLE therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRIPLE therapy (SFC twice daily and tiotropium once daily)
Study: 20377577
Drug: Dual antiretroviral
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiretroviral therapy
Study: 18333706
Drug: Telephone Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone Care Coordination Program (including simple 2‐click referral, proactive care coordination, medication management, and 5 follow‐up telephone calls)
Study: 17028466
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment of patients with HELLP syndrome
Study: 14711132
Drug: Pharmacological interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological interventions (chemical agents)
Study: 14711132
Drug: Behavioral/psychosocial interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral/psychosocial interventions (manual-guided therapy)
Study: 14711132
Drug: Treatment services
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment services
Study: 1581404
Drug: Intensive postconsolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive postconsolidation therapy
Study: 29419653
Drug: Naldemedine 0.2
Normalized name: naldemedine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldemedine 0.2 mg once daily
Study: 17631074
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg plus Simvastatin 20 mg
Study: 17631074
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg plus Simvastatin 80 mg
Study: 16133688
Drug: ALN 5
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN 5 mg once daily
Study: 16133688
Drug: ALN 35
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN 35 mg once weekly
Study: 11845375
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml NaCl 0.9%)
Study: 11845375
Drug: Quintuple prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quintuple prophylaxis (10 mg metoclopramide, 2.5 mg droperidol, 12.5 mg dolasetron, 62.5 mg dimenhydrinate, 8 mg dexamethasone)
Study: 7669374
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine infusion (loading dose of 100 micrograms/kg over 30 min followed by continuous infusion at 10 micrograms/kg per hour)
Study: 8494421
Drug: University of
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: University of Wisconsin solution (UWS)
Study: 6704504
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A and B
Study: 26912209
Drug: Fluticasone/formoterol 500/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol 500/20 μg (high dose)
Study: 26912209
Drug: Fluticasone/formoterol 100/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol 100/10 μg (low dose)
Study: 23344106
Drug: Dronedarone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone (400 mg bid)
Study: 10193670
Drug: enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 20 mg alone